The trajectory of Sildenafil presents a nuanced case for stakeholders in the medicinal sector. While initially a blockbuster success, generating huge profits, the patent lapse and the subsequent flood of off-brand https://pharma784620.blogolenta.com/38820751/viagra-and-big-pharma-a-hazardous-investment